Notch signaling inhibitor shows promise for cancer treatment in Phase I trial
Trial results presented at the 28th EORTC-NCI-AACR Symposium (Munich, Germany) suggest a Notch signalling inhibitor is safe and effective for a range of cancers.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.